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Abstract
This current study aims to systematically review the treatments for anxiety disorders in 
Malaysia. PsycINFO, MEDLINE databases, and 28 local journals were used to search published 
papers in this area. Eight articles were subjected to review after excluding 273 papers that did 
not meet the inclusion criteria. A total of 598 participants with various types of anxiety disorders 
were included in the review. Based on the findings, the combination of pharmacotherapy 
and psychotherapy provided better treatment outcomes if compared to psychotherapy or 
pharmacotherapy alone. The combination of selective serotonin reuptake inhibitors and cognitive 
behaviour therapy was considered as one of the most effective treatment to treat patients with 
anxiety disorders in Malaysia. This is in line with the clinical practice guidelines from the Ministry 
of Health Singapore and Canada. Even though there were some limitations in the methodology and 
reporting of the results, it can be concluded that efforts have been taken to conduct studies related 
to treatments for patients with anxiety disorders in Malaysia. Future studies are suggested to make 
conscious efforts to overcome these limitations. 
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Introduction
One of the most commonly reported mental 
illness worldwide is anxiety disorder (AD) (1). 
As reported in a global meta-analytic review of 
202 studies  conducted in 94 countries (1–2), 
approximately one-eighth to one-sixth of the 
world’s population will experience AD in their 
lifetime. Meanwhile, according to Baxter et al. 
(3), AD is the sixth leading cause of disability, 
in low-, middle- and high-income countries. The 
burden of AD has also been reported through the 
increase in the expenses of  health care services 
and the economic cost for AD since 2005 (3); 
in 2010, the economic cost for AD was 74.4 
billion Euros per year in Europe (4), and in 
Malaysia anxiety is one of the most commonly 
reported and growing mental health problems 
(5). According to the Fourth National Health 
Morbidity Survey (NHMS-IV), the prevalence 
rate of generalised anxiety disorder (GAD) was 
1.7%, which is comparable with international 
figures (1.9%–2.5%) (5). Based on the systematic 
review by Abdul Khaiyom, the prevalence rates 
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benefit ratio (7). In the meta-analytic review of 
57 studies, Bandelow et al. (9) reported large 
treatment effect size (d = 1.83–2.15) for both 
TCA and BZD, while based on the results of the 
systematic review by WFSBP and Singapore 
MOH CPG, the efficacy of TCAs, mainly for 
imipramine and clomipramine, has been well 
proven in the treatment of PD and GAD (7–8). 
Similar to TCAs, BZD has also been used in the 
management of PD and GAD (7) while the use 
Phenelzine, a form of MAOIs, is evident in the 
treatment of SAD and PD (7), (10). Hydroxyzine, 
a drug under NasSA is also being used in GAD 
management due to its sedating effects (6–8). 
Psychological Treatments for Anxiety 
Disorders
There is strong evidence to support the use 
of psychotherapy as a first-line treatment for 
AD. Canadian Psychological Association in their 
meta-analyses on psychological treatments for 
AD argued that the strength of psychotherapeutic 
effects for AD is similar or superior to what 
usually found in the pharmacotherapy effect 
(11). Moreover, as poor compliance from patients 
could result in adverse effects associated with 
pharmacological treatments, Hunsley et al. 
(11) reported that many CPGs have considered 
psychological treatments as the first-line 
treatment for AD. However, this is only relevant 
if the psychological treatments have been 
thoroughly evaluated, made available, preferred 
by the patient, and being conducted by suitably 
trained and supervised therapists (6).
There are many types of psychological 
treatments for AD including Cognitive Behaviour 
Therapy (CBT) and Relaxation Training (RT). In 
the meta-analytic review by Hoffmann et al. (12), 
CBT has been found to be the most researched 
psychological treatment and is endorsed as the 
current gold standard of psychotherapy (13). 
Similar to the above finding, a meta-analytic 
review of 108 trials of CBT for AD concluded that 
CBT effects have been efficacious across AD, and 
greater in active control treatments than non-
treatments (14). Therefore, it is not surprising 
to find that CBT is considered as the first-line 
psychological treatment in many guidelines (10), 
(15–16).
In the meantime, many previous studies 
on psychological treatment of AD have focused 
on RT. There are many forms of RT for AD 
treatment, such as (i) deep breathing (17), 
(ii) progressive muscular relaxation, (iii) 
autogenic (18), and (iv) guided imagery (19). A 
of anxiety among students, general and clinical 
populations in Malaysia range between 1% to 
67.6%, (unpublished data). This indicates the 
paramount need to ensure that patients with AD 
receive proper treatments. 
There are several treatments available 
for people with AD. These treatments can be 
categorised as pharmacological treatment, 
psychological treatment, or a combination 
of both. The selection between these types of 
treatments depends on factors such as i) patient’s 
preference and motivation, ii) treatment options 
availability, iii) adverse medications effects, 
iv) ability/availability of patients to engage/
commit in the treatment, v) severity of illness, 
the presence of co-morbid medical or psychiatric 
disorders, vi) financial considerations, and vii) 
clinicians’ expertise (6–7).
Pharmacological Treatments for Anxiety 
Disorders
A systematic review of 510 randomised 
controlled trials (RCT) by the World Federation 
of Biological Psychiatry (WFSBP) reported 
that selective serotonin re-uptake inhibitors 
(SSRIs) is one of the first-line pharmacological 
treatments for AD [i.e., panic disorder (PD), 
agoraphobia (A), GAD, specific phobia (SP), and 
social anxiety disorder (SAD)] (7). Serotonin-
norepinephrine reuptake inhibitors (SNRIs), 
such as Venlafaxine is also considered the 
first-line treatment for AD (6–8) due to the 
full evidence obtained from RCT. Besides that, 
they also have a good risk-benefit ratio (7). 
Furthermore, Bandelow et al. (9) found large 
treatment effect size (d = 2.09–2.25) in the meta-
analytic review of 85 studies that used SSRIs 
or SNRIs as a treatment for AD. These drug 
treatments are also being practised and outlined 
in the Singapore Ministry of Health (MOH) 
Clinical Practice Guideline (CPG) for AD (8), 
Health Canada CPG for AD (6), and also British 
Association for Psychopharmacology guidelines 
for AD (10). On the other hand, the WFSBP and 
Singapore MOH CPG do not recognise the use 
of psychopharmacological drugs as a standard 
treatment in simple SP cases (7–8), but SSRIs 
can be tried in severe cases (7).
Apart from the above drugs, tricyclic 
anti-depressants (TCAs), benzodiazepines 
(BZD) (7, 10), MAO inhibitors (MAOIs) (10), 
and noradrenergic and specific serotoninergic 
antidepressant (NasSA) (6–7) are also being 
used in the second-line pharmacological 
treatment of AD due to their moderate risk-
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Methods
Literature Search 
In June 2016, PsycINFO and MEDLINE 
databases were searched using the search terms 
anxiety, panic, phobia, distress, and were 
combined with the terms treat*, interven*, 
therapy and Malaysia as identifiers. The 
scope of the search was limited to the title of 
scientific articles published in English or Malay 
from 1980 to 2015, with no restriction of the 
subject area. In addition, 28 local journals were 
manually searched and scrutinised between 
June to December 2016, these journals are 
Malaysian Journal of Psychiatry, International 
Journal of Public Health Research, Jurnal Sains 
Kesihatan Malaysia, Jurnal Psikologi Malaysia, 
Malaysian Journal of Medicine and Health Sciences, 
International Medical Journal of Malaysia, and The 
Malaysian Journal of Medical Sciences. 
Inclusion Criteria
The studies included are those which (i) 
contained treatments used to treat patients with 
AD, (ii) provided information on the outcomes 
of the treatment (iii) conducted for Malaysian 
population, (iv) conducted in Malaysia, and (v) 
published in a peer-reviewed journal.
Data Extraction 
Data were extracted independently by 
one reviewer and entered into data extraction 
forms designed for the review. Another reviewer 
was consulted regarding any discrepancies 
which were resolved through discussion until a 
consensus was reached. 
Encoding Results
The included studies were sorted based 
on the order of publication year. The details of 
the studies were extracted into ten features: (i) 
author/s and year of publication, (ii) participants 
characteristics and settings, (iii) measures used, 
(iv) assessment time, (v) design of the study, 
(vi) intervention/s used, (vii) clinicians who 
conducted intervention, (viii) attrition rate, (ix) 
analysis involved, and (x) findings. 
The encoding criteria were used to 
understand the trend of research design in 
investigating the efficacy or effectiveness of 
treatments for AD in Malaysia. The results will 
be analysed and utilised as the basis for future 
improvements for both clinical and research 
purposes. 
considerable amount of literature has confirmed 
the effectiveness of RT in the treatment of GAD 
(20–22), PD (23), SAD (24–25), and SP (e.g., 
fear of flying and dentist phobia) (26–27). 
Additionally, two meta-analytic reviews have 
supported the effectiveness of RT as a treatment 
for AD in both individual and group sessions 
with effect sizes between moderate (d = 0.57) 
(28) and large (d = 1.36) (9).
Combination of Psychological and 
Pharmacological Treatments for Anxiety 
Disorder 
As pharmacological and psychological 
treatments have their own accessibility and 
effectiveness, the combination of both (termed 
as psychopharmacological treatment) has been 
shown to be a clinically desired AD intervention 
strategy (7). Its effectiveness was proven in the 
meta-analytic review of 16 studies using CBT and 
medication and large effect size (d = 2.12) was 
found (9).
It is also imperative to note that 
psychopharmacological treatment for AD  has 
shown short-term and long-term effectiveness 
with lower drop-out rate, even after the 
termination of pharmacotherapy (9), (29–30) 
and psychopharmacological treatment for AD 
is also more cost-effective (31–32). Meanwhile, 
despite the reported advantages of combined 
treatment, some studies reported that combined 
treatment has no advantage that some of the 
benefits of combined treatment are accounted 
for by pharmacotherapy alone or psychotherapy 
alone (33). 
Nevertheless, it is important to remember 
that the investigations on the combination 
of treatments for AD are still relatively novel 
where much of the cited evidence is from the 
combination of CBT and medications on PD, 
rather than RT and medications. Therefore, this 
current study aims to systematically review all 
available treatments for AD in Malaysia with 
the hopes of bringing additional information 
and potentially new ways of combining 
these treatments to change the now-cautious 
recommendations.
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Results
Search Results
Out of the 281 articles found, 273 were 
excluded for not meeting the inclusion criteria. 
Therefore, eight articles were subjected to the 
review (see Figure 1 for the articles selection 
flowchart). 
Description of Studies
Table 1 shows the included studies on 
the treatments used for patients with AD in 
Malaysia. The earliest study on the treatment 
outcome for AD was in 1992 and the latest in 
2007. No other studies were found between 2007 
and until the literature search was conducted. 
Four out of eight studies were conducted by the 
same person or team (i.e., Azhar and colleagues) 
(34, 37, 39–40).
Study Design
Four of the studies (Study 1, 4, 5, and 7) 
(34, 37–38, 40) reported the use of RCT design 
for conducting trials. Meanwhile one study 
(Study 6) (39) was conducted using non-RCT 
design and another study (Study 3) (36) is a 
controlled trial but the random assignment of 
participants was not reported. Furthermore, 
two studies (Study 2 and 8) (35), (41) are case 
studies.
Participants Involved 
A total of 598 patients with AD were 
included in the review, with sample size ranging 
from 1 to 200. Most of the studies involved 
patients with a specific diagnosis of AD, such as 
PD and GAD. However, only one study (Study 6) 
(39) combined patients with heterogeneous AD 
(i.e., GAD, SAD, and Panic). Moreover, two of the 
studies (Study 5 and 6) (38–39) include patients 
with depression as participants.
In terms of the study setting, six out of 
eight studies were conducted in Kelantan (a 
state in the east coast of Malaysia) and almost 
all the studies were conducted in a university-
based hospitals or clinics. The age range of 
patients with AD was between 24 and 40 years 
old. However, the results are not definitive since 
some studies did not report the data. Moreover, 
there is limited information on gender and 
ethnicities of the patients.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Study selection flowchart 
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Figure 1. Study selection flowchart
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Table 1. Characteristics of included studies
(continued on next page)
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Notes: NR = Not reported. 
Participants: DSM-IV = Diagnostic and Statistical Manual of Mental Disorders 4th ed.; DSM-III-R = DSM 3rd ed-Revision; PD = 
Panic disorder; GAD = Generalised anxiety disorder; PDA = Panic disorder with Agoraphobia; SAD= Social anxiety disorder; OCD 
= Obsessive-compulsive disorder; KL = Kuala Lumpur. 
Measures: SCID = Structured clinical interview; BAI = Beck anxiety inventory; BDI = Beck depression inventory; HARS = Hamilton 
Anxiety Rating Scale; HDRS = Hamilton Depression Rating Scale; PF = Panic frequency per week; Cbs = Catastrophic belief score; 
Bp = Blood pressure; Pr = Pulse rate; DRAT = Daily schedule of automatic thoughts records form; AS-MMPI2s = Anxiety Scale of 
the Minnesota Multiphasic Personality Inventory-2 Supplementary Scale; STAI = State-trait anxiety inventory; Malay valid. = the 
scale has been validated in Malay language version; WHOQOL-BREF = World Health Organization Quality of Life-Brief version. 
Time = Assessment Time: T1 = Baseline; T2 = Mid-treatment assessment; T3 = Post-treatment assessment; T4 = Follow-up 
assessment wk = week; mth = month. 
Design &/ Intervention: RCT = Randomised controlled trial; NRCT = Non-randomised controlled trial. Interventions: CBT 
= Cognitive behaviour therapy; RCPwCM = Religious-Cultural Psychotherapy with Beck’s Cognitive Model; RSP = Religious & 
Supportive Psychotherapy; SP = Supportive Psychotherapy; RSCP = Religious-Sociocultural Psychotherapy; RLX = Relaxation 
Exercise; ESC = Escitalopram; STR = Sertraline; FXT = Fluoxetine; FVX = Fluvoxamine; BZD = Benzodiazepines; wk = week, min 
= minutes. 
Analysis: ITT = Intention-to-treat analysis; PP = Per-protocol analysis; Sig. test = Significant testing for mean difference (e.g., t-test, 
ANOVA); CC = Report clinical significance change. 
Findings: +ve = interventions used are generally effective in improving the patients’ conditions during assessments/post-treatment/
at follow-up; Sig. diff. = significant difference/s; +++ =  Experimental group has large treatment effect size at post-treatment. 
Table 1. (continued)
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Measures Used 
A majority of studies reported the use of 
Diagnostic and Statistical Manual of Mental 
Disorders (DSM) as a diagnostic measure to 
assess AD. However, only Study 3 (36) reported 
the use of a Structured Clinical Interview for 
DSM Disorders in confirming the diagnosis of 
patients with AD. 
In the meantime, most of these studies 
used more than one self-report measure and 
most used were anxiety symptoms measure 
such as Hamilton Anxiety Rating Scale (HARS) 
and Beck Anxiety Inventory (BAI). Some of the 
studies have incorporated the use of depressive 
symptoms measure to assess the comorbid 
symptoms of depression among patients with 
AD. The most used measures to assess depressive 
symptoms are Hamilton Depression Rating Scale 
(HDRS) and Beck Depression Inventory (BDI). 
Apart from the above measures, other 
ecologically valid measures relevant to anxiety 
were minimally used in the studies. For example, 
only one study used WHO Quality of Life-
BREF measure (WHOQOL-BREF), two studies 
reported the use of cognitive-based measures 
(i.e., Catastrophic Belief Score and Daily 
Schedule of Automatic Thoughts Record Form), 
and two studies used validated religiosity scale in 
the Malay language. 
Time of Assessments
A majority of these studies conducted 
baseline assessment to assess the patients’ 
conditions prior to the treatment; middle-
treatment assessments were conducted by Study 
2 (35) and Study 4 (37) to measure if there were 
treatment gains prior to the completion of the 
treatment received. Three studies specified the 
conduct of post-treatment assessments (i.e., 
immediately after the treatment was completed) 
to measure the effectiveness of treatment 
received by patients. 
Some of the studies also specified the 
time of assessments (e.g., at 4th week, at 
12th week, at 26th week, at 3-month, and at 
6-month). However, due to unclear reporting 
on the intervention status (i.e., patients are still 
receiving the intervention or not), it could not be 
confirmed if the assessments are post-treatment 
assessments. Only study 8 (41) reported a 
confirmed follow-up assessments using phone 
calls and letters on the 6th and 12th month after 
the completion of treatment.
Details of the Interventions Used
Interventions used to treat AD in Malaysia 
can be categorized in three general approaches: 
(i) pharmacotherapy alone, (ii) psychotherapy 
alone, and (iii) combination of pharmacotherapy 
and psychotherapy.
i. Pharmacotherapy alone
One of the treatment arms in Study 4 (37) 
used only fluvoxamine (FVX) to treat patients 
with AD. The dosage of FVX was specified 
(i.e., start at 50mg/day to 200mg/day) and 
the treatment session was reported (i.e., nine 
sessions).
ii. Psychotherapy alone
Four studies only used psychotherapy as 
either a part of their treatment arm, or as the 
only treatment option. For example, Study 2 
(35), Study 4 (37), and Study 6 (39) used CBT as 
their treatment. On the other hand, Study 8 (41) 
used hypnosis and RT. 
A majority of the studies reported the 
number of treatment sessions, for example, 
Study 2 (35) and Study 4 (37) conducted twelve 
and nine CBT sessions, respectively. Whereas, 
Study 8 (41) conducted only one session of 
hypnosis and RT. None of the studies informed 
the duration of each treatment session. 
Only Study 2 (35) detailed out the treatment 
protocol used while Study 4 (37) only reported 
the guidelines. However, none of the studies 
reported the use of specific published treatment 
manual as the reference for their treatment 
protocol.
iii. Combination of pharmacotherapy and 
psychotherapy 
Five studies used the combination of 
pharmacotherapy and psychotherapy. Study 
1 (34) and Study 4 (37) used CBT as the 
psychotherapy and the pharmacotherapy 
used were from different types of SSRIs (i.e., 
escitalopram-ESC, sertraline-STR, fluoxetine-
FXT, and FVX). On the other hand, Study 3 (36), 
Study 5 (38) and Study 7 (40) used religious 
and cultural-based supportive psychotherapy. 
Study 3 also reported the incorporation of Beck’s 
Cognitive Model as part of the elements in the 
therapy. Meanwhile, in these studies BZD was 
used as pharmacotherapy treatment. From these 
five studies, only Study 1 (34) and Study 4 (37) 
reported the dosage of pharmacotherapy given. 
The duration of pharmacotherapy ranged 
between seven to 16 weeks, whereas, the 
psychotherapy session ranged between nine to 
16 sessions (37), (40). However, the information 
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is not definitive since Study 3 (36) and Study 5 
(38) did not report the number of their treatment 
sessions while only Study 7 (40) reported the 
duration of each treatment session, (i.e., 45 min). 
All five studies generally described the 
elements used in the therapy. However, there 
is no report on the use of specific published 
treatment manual as the reference for their 
treatment protocol and the studies did not report 
whether the psychotherapy were conducted in 
individual or group format. 
Clinician
Almost all of the pharmacotherapy and 
psychotherapy treatments in the studies were 
conducted by psychiatrists, except for Study 2 
(35). In the study, the treatment was conducted 
by a clinical psychologist. Meanwhile, Study 
7 (40) did not report the involvement of any 
clinician in the treatment. None of the studies 
reported how many clinicians involved in 
conducting the treatments.
Attrition 
All studies, except for Study 1 (34), reported 
the attrition rate between 0% and 50%. In 
general, patients’ drop-out occurred due to the 
patients’ inability to complete the minimum 
requirement of the therapy (e.g., six months of 
therapy). Moreover, only Study 4 (37) mentioned 
the time relative to the attrition rate (i.e., during 
the treatment, after the completion of treatment, 
during follow-up).
Analysis
All of the studies, except Study 2 (35) and 
Study 8 (41) which utilised case study design, 
conducted significant testing to analyse the 
effectiveness of treatments received by the 
patients. Out of four studies utilising RCT design, 
only Study 4 conducted intention-to-treat (ITT) 
analysis while other two studies, Study 5 (38) 
and Study 7 (40), used per-protocol (PP) analysis 
and one study (Study 1) did not report the use of 
either ITT or PP analysis (34).
None of the studies reported the effect size 
of the treatment outcome. However, the readers 
may manually calculate the effect size using 
the mean, standard deviation, and number of 
samples in the group provided. 
General Findings
All studies reported positive improvements 
in patients with AD after receiving the 
treatments, but only Study 4 (37) able 
to compare the effectiveness of the three 
treatment approaches (i.e., a combination 
of pharmacotherapy and psychotherapy, 
psychotherapy alone, and pharmacotherapy 
alone) and it was found that the combination 
of CBT with FVX, or CBT alone provide greater 
improvements to patients with AD if compared 
to FVX alone. 
Furthermore, Study 6 (39) found that CBT 
is more effective if compared to supportive 
psychotherapy and patients were found to 
improve continuously at the 6-month follow-
up. Other than the above, RSCP or RSP with 
a combination of BZD (refer Study 3, Study 5, 
and Study 7) (36, 38, 40) are more effective if 
compared to the treatment using supportive 
psychotherapy with BZD. This provides evidence 
on the importance of religion and socio-cultural 
elements as part of the treatment component for 
patients with AD in Malaysia. 
Discussion
This study aims to systematically review 
the treatments for anxiety disorders in Malaysia. 
Based on the review, in Malaysia, AD is treated 
using either pharmacological treatment, or 
psychological treatment, or the combination 
of both. Significant improvement with large 
effect sizes were seen in the patients with PD 
treated using combination of psychotherapy 
and pharmacotherapy (CBT with FVX) or 
psychotherapy alone (CBT) (37). This is in line 
with the study conducted by Bandelow et al. (7) 
who found the combination between CBT and 
medication was shown to have the best treatment 
outcome. In addition, Katzman et al. (6) in their 
clinical practice guidelines for the management 
of anxiety argued that pharmacological 
treatments can enhance the efficacy of CBT. 
Nonetheless, the knowledge about the use of 
combination treatments for AD relies heavily 
upon empirical studies on PD using CBT and 
medications.
In addition, this review revealed that 
either RSCP or RSP with a combination of SP 
and pharmacotherapy were more effective 
(refer to Study 3, 5, and 7) than using SP with 
pharmacotherapy only (36, 38, 40). This 
illustrates that religio-socio-cultural aspects play 
a vital role in the treatment of AD in Malaysia 
since Malaysians are deemed as a cultural and 
religion oriented nation (36). Furthermore, 
Razali et al. (36) suggested that therapeutic 
relationships between patient and mental health 
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service providers can be strengthened when 
cultural aspect is taken into considerations. 
Thus, incorporating RSCP or RSP in the 
treatment of AD may have great benefit, since it 
has been long known that cultural background 
may influence the therapeutic relationships 
between patients and healthcare professionals 
(36). 
Limitations and Recommendations for 
Improvements
There are several limitations found on the 
studies reviewed. It is hoped that future studies 
will be able to bridge the gaps found in the 
literature.
Time of studies
It was surprising to find that the most 
recent research on treatments of AD in Malaysia 
was published in 2007. Moreover, most 
published research found have been conducted 
primarily by the similar team of researchers 
(i.e., Azhar–a psychiatrist-and his colleagues). 
Hence, this area of research is still in an infantile 
stage and there are vast opportunities for future 
discoveries. Based on the high prevalence rates 
of anxiety in Malaysia (5) (unpublished data), 
future research needs to focus on treatment 
outcome studies. This is to ensure health care 
providers are ready to provide empirical and 
evidence-based treatments for patients with AD 
in Malaysia.
Power and sample size calculation
Most of the studies reviewed have a 
very small sample size and this is considered 
as a serious limitation. Besides that, none 
of the studies provided power and sample 
size calculations in their paper, hence, the 
results may be biased to Type-I error whereby 
researcher may conclude that the supposed 
treatment effectiveness exists when in fact it does 
not (42–43). 
Location of studies
Most of the studies were conducted in 
the eastern part of Malaysia and there are very 
few studies conducted in the central part of 
Malaysia, especially in the Klang Valley which 
is the most populated area in Malaysia besides 
constituting the largest urban centre in the 
country (44). According to Institute of Public 
Health (5), mental health problems, including 
AD were found to be more prevalent in urban 
areas compared to rural areas. Therefore, it is 
suggested that future research on treatment 
outcome is conducted in the central part of 
Malaysia, especially in the Klang Valley.
Since most of the studies were conducted 
in university-based hospitals or clinics (i.e., 
academic or research setting), it is not certain 
that the treatments used in the studies could be 
generalised and transported to public health 
settings, such as government hospitals. Future 
research is encouraged to bridge this gap by 
conducting research on different settings to test 
the generalisations of treatments and its results. 
Details of participants
Most of the studies reviewed did not report 
the information related to gender and ethnicities. 
Therefore, the important demographic 
information of the patients were missing, this 
has limit our understanding on the epidemiology 
of patients with AD in Malaysia.
Assessments used and issue of 
multiplicity adjustments
While some of the studies used more than 
one anxiety symptoms measures, none of the 
studies reported their primary outcome measure 
and the adjustment for multiple comparisons 
(e.g., using Bonferroni-type adjustment). 
According to Tyler et al. (45), no correction for 
a multiplicity of treatment outcomes may inflate 
the risk of Type-I error. 
Meanwhile, a small number of studies used 
the depressive symptoms measure to assess 
the effect of treatments on the comorbidity 
symptoms and very few studies used other 
ecologically valid measures such as quality of 
life and cognitive measures. Convergence in 
outcomes across these numerous measures will 
provide more convincing evidence of positive 
treatment outcomes.  Therefore, there is a need 
to evaluate the effectiveness of treatments for 
AD in Malaysia with a broader range of outcome 
measures. 
Moreover, none of the reviewed studies 
reported the use of validated outcome measures 
for anxiety symptoms, depressive symptoms, 
and quality of life. Based on the limitations 
presented, future studies are encouraged to 
be more careful in the utilisation of outcome 
measures to ensure the validity of the results.
Reporting of assessment time, study 
design, and treatment procedures
The reporting of most studies related to 
assessment time (i.e., baseline, mid, post, and 
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of a research investigation. Effect size is the 
magnitude of the difference between treatment 
groups (50–51). Even though a significant 
statistical value (e.g., P < 0.05) can inform 
the reader whether an effect exists, it will 
not reveal the size of the effect. Moreover, it 
is vital to report the effect size for treatment 
outcome studies in Malaysia since it will assist 
future researchers to calculate the number of 
participants sufficient in their studies. This 
is to avoid a Type-II error (the probability of 
concluding there is no effect when one actually 
exists).  
In addition, only one study provides clinical 
significant change analysis (CC) and none of the 
studies provided reliable change analysis (RC). 
These two analyses are important for researchers 
and clinicians to communicate with patients on 
the treatment effects pragmatically. Due to this, 
future research is encouraged to include not 
only significant testing and effect sizes in their 
analysis but also RC and CC.
Conclusion
Even though the studies reviewed have 
shown some limitations in the methodology and 
reporting of the results, it can be concluded that 
these studies have taken the efforts to conduct 
studies on treatments for patients with AD in 
Malaysia. Based on the review, the combination 
of pharmacotherapy and psychotherapy 
provided better treatment outcome if compared 
to psychotherapy or pharmacotherapy alone. 
Furthermore, it can be seen that CBT treatment 
was considered as one of the treatments of choice 
for psychological intervention to treat patients 
with AD in Malaysia. This is in-line with the 
clinical practice guidelines from Singapore (8) 
and Canada (6). However, it is recommended 
for future studies to make conscious efforts 
to minimise the weaknesses that have been 
discussed previously. 
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follow-up treatment) was not clear which could 
impose difficulties for future researchers to 
design related studies. 
Furthermore, even though a majority of 
the studies claimed that they used RCT as their 
study design, the studies did not specifically 
report the procedures of enrollment, allocation 
and randomisation, follow-up, and analysis. For 
example, majority of the studies lacked in terms 
of (a) reporting of the treatment procedures, 
such as the duration of each treatment session, 
(b) reporting on the use of treatment manual to 
confirm standardisation of treatment received 
by each patients, (c) information on how many 
clinicians involved in conducting the treatments, 
(d) information whether the treatment being 
conducted in individual or group format and 
(e) information related to assessment time and 
attrition rate. This raised concern about the 
quality of the RCT studies being conducted. 
Therefore, future studies are very much 
encouraged to conduct and report RCT studies in 
accordance with CONSORT guideline (46).
Clinicians involved in the studies
The majority of the studies were conducted 
by psychiatrists who were known to be trained 
in the prescription of medications as part of 
mental disorders management. According to Ng 
(47), conducting psychological assessments and 
psychological interventions are not part of the 
compulsory training received by the psychiatrist. 
Therefore, clinical psychologists who are 
trained in both psychological assessments and 
psychological interventions such as CBT and RT 
are very much encouraged to collaborate with 
psychiatrists in conducting treatment outcome 
studies related to AD. This is supported by 
Abdul Wahab Khan (48) who argued that clinical 
psychologists are highly needed in Malaysia due 
to their ability to both diagnose and provide 
psychological interventions for mentally ill 
patients.  
Analysis used in the studies
The current systematic review found that 
limited RCT studies used ITT analysis. The 
issues of non-compliance protocol deviations, 
attrition or withdrawal, or anything that happens 
after randomisation treatment assignment 
are balanced by the use of ITT analysis (49). 
Therefore, RCT studies need to use ITT as part of 
their statistical analysis.
Moreover, none of the studies reported 
treatment effect sizes which are the key product 
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